FDA Expands Approval of Osimertinib in Lung Cancer

Published Date: 30 Sep 2024

EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.

2.

RML to develop bone marrow transplantation at Lady Hardinge Medical College in Safdarjung

3.

In a study, immune detection of oral cancers is linked to obesity.

4.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

5.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot